Provided a corporate update. Further to Antibe’s update of February 15, 2023, the Company has now selected a clinical research organization to carry out the pharmacokinetic/pharmacodynamic study for otenaproxesul’s new formulation. The purpose of the PK/PD study is to confirm the optimal dosing regimens for the Phase II bunionectomy trial, slated to initiate in calendar Q4 2023 as previously announced. Antibe Therapeutics Inc. shares T.ATE are trading down $0.02 at $0.54.
Stocks in play: Antibe Therapeutics Inc.
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)